Omnicell (NASDAQ:OMCL) PT Set at $55.00 by Piper Sandler

Omnicell (NASDAQ:OMCL) has been assigned a $55.00 target price by analysts at Piper Sandler in a research report issued to clients and investors on Monday, MarketBeat reports. The brokerage currently has an “overweight” rating on the stock. Piper Sandler’s price target points to a potential upside of 75.49% from the company’s current price.

OMCL has been the subject of several other research reports. Wells Fargo & Company upped their price objective on shares of Omnicell from $37.00 to $40.00 and gave the stock an “overweight” rating in a report on Monday, July 21st. Benchmark dropped their price target on shares of Omnicell from $62.00 to $40.00 and set a “buy” rating on the stock in a research report on Wednesday, May 7th. Wall Street Zen downgraded Omnicell from a “strong-buy” rating to a “buy” rating in a report on Saturday. Finally, Bank of America boosted their price objective on Omnicell from $30.00 to $34.00 and gave the stock a “neutral” rating in a report on Friday, May 23rd. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Omnicell presently has an average rating of “Moderate Buy” and a consensus price target of $46.71.

Omnicell Stock Performance

OMCL traded down $0.20 during trading hours on Monday, hitting $31.34. The company’s stock had a trading volume of 494,428 shares, compared to its average volume of 594,596. Omnicell has a fifty-two week low of $22.66 and a fifty-two week high of $55.74. The company has a current ratio of 1.42, a quick ratio of 1.24 and a debt-to-equity ratio of 0.13. The firm has a market capitalization of $1.44 billion, a PE ratio of 62.68, a PEG ratio of 9.20 and a beta of 0.78. The company has a 50-day simple moving average of $29.43 and a 200 day simple moving average of $32.52.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Thursday, July 31st. The company reported $0.45 earnings per share for the quarter, topping the consensus estimate of $0.30 by $0.15. The business had revenue of $290.56 million during the quarter, compared to the consensus estimate of $275.57 million. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. The company’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.51 earnings per share. As a group, sell-side analysts expect that Omnicell will post 1.09 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in OMCL. Alliancebernstein L.P. raised its holdings in shares of Omnicell by 4.3% in the fourth quarter. Alliancebernstein L.P. now owns 55,922 shares of the company’s stock valued at $2,490,000 after buying an additional 2,316 shares during the last quarter. Wells Fargo & Company MN raised its holdings in shares of Omnicell by 27.3% in the fourth quarter. Wells Fargo & Company MN now owns 132,252 shares of the company’s stock valued at $5,888,000 after buying an additional 28,390 shares during the last quarter. Invesco Ltd. raised its holdings in shares of Omnicell by 2.4% in the fourth quarter. Invesco Ltd. now owns 219,453 shares of the company’s stock valued at $9,770,000 after buying an additional 5,063 shares during the last quarter. Legal & General Group Plc raised its holdings in shares of Omnicell by 3.2% in the fourth quarter. Legal & General Group Plc now owns 352,700 shares of the company’s stock valued at $15,702,000 after buying an additional 10,847 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of Omnicell by 79.3% in the fourth quarter. Renaissance Technologies LLC now owns 456,343 shares of the company’s stock valued at $20,316,000 after buying an additional 201,831 shares during the last quarter. 97.70% of the stock is owned by institutional investors.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.